A team from the Scripps Research Institute have determined the structure of clade C HIV-1 envelope glycoprotein, an immunogen that could be utilized in a future HIV vaccine.
Browsing: Basic > Pre-clinical Trials
Development of protein vaccine to prevent congenital infection is a public health priority, this research investigates the design of a mucosal synthetic pathogen as a vaccine strategy against congenital toxoplasmosis.
The recurring resistance of the malaria parasite to many drugs compels the design of innovative chemical entities in antimalarial research. In light of this, the authors discuss thiaheterocyclic hHDAC6 inhibitors as potentially powerful novel antimalarials.
John-Arne Røttingen discusses his role as founding CEO of the Coalition for Epidemic Preparedness Innovations (CEPI) and his thoughts on the importance of developing new vaccines for emerging threats.
In new research, the first live-attenuated Zika vaccine has been demonstrated to protected mice against the virus after a single dose.
Take a look at our new infographic, developed for World Tuberculosis Day, which explores the facts about current TB burden, the issues around drug resistance, and research and development moving forwards.
Study demonstrates the value of phage therapy in effectively treating Pseudomonas aeruginosa infections.
Researchers have pioneered an mRNA-based vaccine against Zika that has demonstrated promising results in pre-clinical trials on mice and monkeys.
In this editorial the authors discuss the potential of zinc oxide nanoparticles as an immunotherapy against genital herpes infections.